Marion Abecassis

• Advising Halma, the global group of life-saving technology companies, on the cross-border acquisition of 100% of the shares and voting rights in French-based Lamidey Noury Medical, reinforcing its international footprint between France and England & Wales.
• Advising Pierre Fabre on the sale of the Centre Immunologie Pierre Fabre in Saint-Julien-en-Genevois, together with the R&D activities carried out on this site, to Jubilant Group.
• Advising Pierre Fabre on the contemplated acquisition of the European rights to certain oncology products from a US-UK group, including marketing authorisations, inventories, and dedicated employees, supported by an in-depth multi-jurisdictional strategic analysis (corporate, tax, IP, labour, regulatory and antitrust).
• Advising Pierre Fabre Group on the acquisition of Vertical Bio, a Basel-based drug discovery and development company incubated by Ridgeline Discovery (Versant Ventures).
• Advising Sanofi on the preparation of major R&D and manufacturing contracts, including regulatory analyses of direct-to-patient services in decentralized clinical trials, medicines distribution rules in France, and regulatory/data-protection aspects of pre-screening and home-nursing activities.
• ·• Advising Sanofi in connection with its contemplated transaction with CD&R regarding a controlling interest in Opella, including operational contracts (manufacturing and licensing) for the industrial disentanglement of Opella and Sanofi at site level (Tunisia, Brazil, Mexico, the US and Japan) and defining the global digital-asset separation strategy, in coordination with IP experts.
• Advising Eurazeo and its fund Nov Santé Actions Non Cotées, dedicated to the development of the healthcare sector in France, on its acquisition of a share in the Moria group, a company renowned for its expertise in the production and marketing of instruments and pharmaceutical products for ophthalmic surgery.
• Advising Stryker, a US medical technology company, in the context of the acquisition of Serf SAS, a medical device manufacturer/seller that is a wholly owned subsidiary of a French company, located near Lyon France.
• Advising Reata Pharmaceuticals on preparations for the EU and UK market launch of a pipeline medicinal product, including regulatory guidance, drafting of commercial contracts and templates, supply-chain and import considerations, and compliance with rules governing interactions with Key Opinion Leaders, MSLs and other healthcare professionals, as well as corporate and employment matters.
• Advising Kartos Therapeutics on establishing its clinical research operations in Europe.

Individual recognitions

• Best Lawyers “Ones to Watch” – Biotechnology and Life Sciences Practice, Corporate Law and Health Care Law – 2024-2026
• “Regulatory Rising Star” - LMG Life Sciences Awards 2023 EMEA
• Marion is ranked “Excellent” for “Healthcare, pharmaceuticals & biotech / Regulatory” and “Highly Recommended” for “Healthcare, pharmaceuticals & biotech / Capital, joint venture, and corporate transactions” in France in the 2022 and 2021 Décideurs Legal League ranking.
• Fulbright Grantee 2014
• Lauréate de la Fondation Monahan 2014
• Lauréate de la Fondation Georges Lurcy 2014

Team recognitions

• Chambers France – Pharma/Life Sciences – Band 4 – 2025

“The team have deep knowledge of our industry and a strong track record.”

“I like the firm's knowledge of the market and our company, their availability and their responsiveness.”

“The firm answers my needs in terms of cross-practice skills, values and empathy. The lawyers listen to the clients and they are available.”

“I am satisfied with their interpersonal skills with the client and their ability to be a real business partner.”

• Legal 500 - Industry Focus: Healthcare and Life Sciences - Tier 2 – 2025

“International firm with extensive expertise. Interest in complex cases requiring varied and highly specialised resources and expertise.”

“Skills in the health sector and diversity in areas of expertise (litigation, administrative, regulatory).”

“The team is very cohesive and diligent in implementation. It is very experienced in acquisitions, divestments and industrial contracts in the field of pharmaceuticals and medical devices. It has good international experience and benefits from a competent network in the field, particularly in the US.”

• Legal 500 - Private Equity: LBO - Tier 3 – 2025

Availability, in-depth expertise, ability to support both SMEs and large international groups.”

• Legal 500 - Mergers & acquisitions - Tier 4 – 2025

"Great organisational capabilities combined with a focused professional approach and excellent connections worldwide.”

• Option Droit & Affaires – Mergers & acquisitions – 5 stars – 2025
• Option Droit & Affaires – Private Equity – 5 stars - 2025

• “What every life sciences lawyer need (commercial contracts)”, Episode 8 - Clinical trial agreements, 8 February 2024
• Managing expectations, rights, and duties in large-scale genomics initiatives: a European comparison , European Journal of Human Genetics, 6 December 2022
• Assisted Reproductive Technologies: impact on current law and future prospects, Cycle de conferences du Master Comparative Health Law, Mars 2022
• “Organoids: science fiction or the future of pre-clinical studies?”, DLA Cortex Blog, October 2022
• “Intelligence Artificielle et Sciences de la vie : des espoirs thérapeutiques aux défis éthiques et juridiques”, Guide du Numérique de DLA Piper, July 2022
• “Raw material shortage and its impact on the pharma industry”, Cortex Blog, 24 May 2022
• « Nouveau chapitre dans la saga judiciaire relative au CBD », La Lettre des juristes d’affaires, 31 January 2022.
• Nouveau chapitre dans la saga judiciaire relative au CBD, La Lettre des juristes d’affaires, 31 January 2022
• « Vaccin contre le Covid-19 : « L’éthique exige que soit garanti l’accès pour tous aux données scientifiques », Tribune co-signée dans le Monde, 15 December 2020
• Quoted in the newspaper article “Bébés OGM : les comités d’éthique français, allemand et britannique presque à l’unisson”, Florence Rosier, Le Monde, 1 March 2020
• Fostering responsible research with genome editing technologies: a European perspective, Springer International Publishing, Transgenic Res (2017) 26: 709, July 2017
• Artificial Wombs: "the Third Era of Human Reproduction" and the Likely Impact on French and U.S. Law, Hastings Women's Law Journal, January 2016

• Penser nos droits : quelle protection pour nos cerveaux ? », 12e Journée annuelle du Comité d'éthique de l'Inserm le 15 October 2025
• Panel “Negotiation of International Clinical Trial Agreements”, 6th Clinical Trial Agreements Summit in Philadelphia, 21 August 2025
• France-US Crossed-Views Life Sciences Growth and Investment Strategies, DLA Piper, 22 May 2025
• Webinar “Telehealth Around the World” for the American Telemedicine Association, 17 October 2024 Masterclass “Health Data in Europe: Challenges in an Evolving Regulatory Framework”, AI for Health, October 2024
• “CRISPR et médecine translationnelle : sujets éthiques et juridiques”, CRISPR and Translational Medicine Congress of Bordeaux University, April 2022 (Bordeaux, France)
• « Quelle place pour l’éthique dans l’innovation en santé ? », Grande Conférence Medintechs, March 2022 (Paris, France)
• “Assisted Reproductive Technologies: impact on current law and future prospects”, Cycle de conferences du Master Comparative Health Law, March 2022 (Paris, France)
• “A qui appartiennent les données génétiques ? ”, Congrès annuel de la Société Française de Médecine Personnalisée et Prédictive, 30 September 2021 (Paris, France)
• “Use of Genome Editing in Humans: Legal Challenges”, Young Researchers in Biology of AURA Region Congress, 21 June 2021 (virtual meeting)
• “L’épopée des vaccins anti-covid”, Conférence Interprofessionnelle de Sub’ Biotech Ecole de Biotechnologies, 30 March 2021 (virtual meeting) 
• “Legal and Ethical Challenges of Genome Editing”, Lecture at Sciences Po, April 2020 (virtual lecture)
• “ IA dans les deals life sciences”, Intervention in the Master 2 droit des affaires appliqué au monde de la santé, Faculté de droit de l’Université de Saint-Etienne, 25 February 2020 (Saint-Etienne, France)
• “Les enjeux de l’édition génomique entre craintes et espoirs », Entretiens Nîmes-Alès à l’Ecole de l’ADN, 8 February 2020 (Nîmes, France)
• “Genome Editing: a Global Legal Perspective”, Transgenic Technology Meeting TT2019, 7 April 2019 (Kobe, Japan)
• "Ethical Challenges in Gene Banking and Gene Editing", PHREB 2nd Biennial Conference, 27 November 2018 (Manilla, Philippines)
• Moderation of panels at annual ARRIGE Meetings, November 2018 – 2020 (Paris, France)
• Marion has co-founded a think tank gathering international stakeholders focusing on the ethical use of genome editing (ARRIGE - Association for Responsible Research and Innovation in Genome Editing).